NONE 7/3/2018 MY MANTRA: SIMPLE, SAFE, CHEAP TWO ITCHY PEARLS ZINC! CONFLICT OF INTEREST DISCLOSURE

Size: px
Start display at page:

Download "NONE 7/3/2018 MY MANTRA: SIMPLE, SAFE, CHEAP TWO ITCHY PEARLS ZINC! CONFLICT OF INTEREST DISCLOSURE"

Transcription

1 TOTALLY RADICAL SYSTEMIC THERAPEUTIC PEARLS {SOMETIMES BASED ON BASICS} {Sometimes Based on Faith} Radical Pearls Hong Kong Jade Market 2014 CONFLICT OF INTEREST DISCLOSURE NONE Ninguno Nessuno Aucun Keiner Ни один 無なし없음 MY MANTRA: SIMPLE, SAFE, CHEAP 70% Psoriasis patients itch ¾ of them itch daily ASPIRIN relieves PsO itch TWO ITCHY PEARLS No-reason itch Negative work up Paroxetine 20mg QD Aropax, Brisdelle, Deroxat, Paxil, Pexeva, Paxtine, Paxetin, Paroxat, Paraxyl, Sereupin, and Seroxat. Skin Therapy Lett 13:6, 2008 ZINC! ZINC: FAST FACTS: LOW ZINC LEVELS ASSOCIATED WITH Immune deficiency: macrophage and neutrophil function, lymphocyte activation / proliferation, complement activity; loss of modulation of TNFα and NO species Delayed wound healing: decreased matrix metalloproteinase activity, decreased keratinocyte migration, increased keratinocyte apoptosis Autoimmun Rev. 2015;14: Wound Repair Regen. 2007;15(1):2-16 1

2 ZINC RX FOR MOLLUSCUM? Open label trial (Korea; n=59) Zinc sulfate 10mg/kg/day (maximum 600mg) Rx done up to 6 months (Mean to success only 4 mo) COMPLETE clearance 47.5% PARTIAL clearance 25.4% CR + PR = 73% Well tolerated (constipation 3%, nausea 1%) ZINC RX FOR VERRUCA? Multiple trials (Korea and Brazil) Zinc sulfate 10mg/kg/day (maximum 600mg) Rx done up to 3 months? MOA; Maybe increases APC activity % success rate reported Failures ascribed to too low a dose, noncompliance due to GI symptoms, or too short treatment regimen Patients do better when serum Zn levels rise by end 1-2mo J Am Acad Dermatol 2016;74(Suppl1):AB162 Br J Dermatol 2002;146:423-31; JAAD 2009;60: ; Ann Bras Dermatol 2009;84:23-29 Clin Exp Dermatol 2009;34:e984-85; J Dermatol 2011;38: ZINC: CAUTION! Warts From Hell Gastritis to gastric perforation; To avoid this. Always give in divided doses Always give after meal Do not exceed mg elemental zinc per day Zinc sulfate: Multiple mg x 23% = elemental Zn Zinc gluconate: Multiply mg x 13% = elemental Zn Six children 9-11yo Recalcitrant warts: palmar or plantar or both Failed: Salicylic acid, Duct tape, Cryo LN 2, Imiquimod, 5-FU, CO 2 laser, Cimetidine 4vHPV x 3 shots (full series) Appropriate age timing for vaccine! Approved and recommended ALL clear non-genital warts (6 of 6) QUADRIVALENT HPV VACCINE EXTRAGENITAL CUTANEOUS WARTS Acta Derm Venereol. 95:1017-9, 2015 HPV VACCINE AND COMMON WARTS 17-yo with idiopathic neutropenia/lymphopenia Multiple common and plantar warts Resistant to cryosurgery, imiquimod, OTCs Given 4vHPV vaccine: after third injection: all warts gone Message: Administration of HPV vaccine (indicated > age 9) may lead to resolution of common/plantar warts Clin Exp Dermatol. 2017;42:

3 HYPERTHERMIA Vasodilation: increased immune cells Upregulates TSLP: recruits immune cells Increased activity T- and B- cells Increased phagocytosis pmn s Increased cytokine release Direct toxic effect on microbes HYPERTHERMIA Sporotrichosis Chromoblastomycosis Leishmaniasis Atypical mycobacteria HSV-1, HSV-2 J Am Acad Dermatol. 2010;62: J Am Acad Dermatol. 2010;62: HYPERTHERMIA AND HSV-1 OR HSV-2 Small handheld device Approved everywhere but USA Emits C heat x 4 seconds 1-2 applications shortens HSV-1 course to 1.85 days (mean) 1-2 applications shortens HSV-2 ~$100; need refills of heat generating cartridge E-Bay, Amazon Praktische Dermatologie. 2011;17: Clin Cosmet Investig Dermatol Jun 5;6:163-6 HYPERTHERMIA AND MOLLUSCUM HEATING PAD Small (n=21) Chinese prospective study; patented IR heating unit 44 0 C (111 0 F) for 30 minutes, once weekly x 12 weeks 13 children, 8 sexually active adults (ages 21-28) Average # lesions = 59 (ie. Bad molluscum) 12/18 complete clearance 12 weeks (children & adults) Facial lesions relatively resistant compared to other sites Br J Dermatol. 2017;176:

4 TINEA VERSICOLOR Stronger warning issued ; Don t use ketoconazole! Alternative orals (off label) Itraconazole 400mg/d x 3d or 200mg/d x 5d J Dermatolog Treat 2002;13:185-7 Fluconazole 300mg QWk x 2 Mycoses 2007;50: VITAMIN D AND INFLAMMATION Vitamin D attaches to both nuclear receptors and transmembrane receptors Alters transcription pattern within cell In general (macrophage/monocyte/lymphocytes) Decreases TNFα, IL-12 Increases IL-4, IL-10 Interaction with mast cells: decreases inflammatory mediator release (histamine, leukotrienes) Histamine, Leukotrienes From mast cells.. HIVES! Int J Biochem Cell Biol. 2011;43:41-6 Exp Dermatol. 2009;18: VITAMIN D RX FOR CHRONIC IDIOPATHIC URTICARIA? Vitamin D levels often low (deficient/insufficient) in CIU IF Vitamin D level < 30ug/L, consider Vitamin D therapy How much? ,000 IU Vitamin D3 daily in literature I give 10,000 IU daily ADJUNCT to typical high dose antihistamine therapy Better response Quicker response Response rates 70+% to 90+% J Dermatolog Treat. 2016;27:163-6 World Allergy Organ J Jun 4;8(1):e15 Dermatoendocrinol Jul 16;6:e29727 Simple, Safe and Cheap Ann Allergy Asthma Immunol. 2014;112: ALOPECIA AREATA 4

5 ALOPECIA AREATA?FEXOFENADINE? Widely utilized in Japan as an adjunctive or even as primary monotherapy Mechanism of action: may prevent mast cell degranulation;? part of AA etiology Simple, safe, cheap: Can be used long term Dose: mg/d (adult) 15-30mg/d (child > 6mo) Available: 30, 60,180mg tab, 30mg/5cc susp and 30mg dissolving tab J Dermatol 39:1063, 2012 J Dermatol 36:323, 2009 J Dermatol 34:852, 2007 COMMON PROBLEM: SENILE (SOLAR) PURURA J Drugs Dermatol 10:718-22, 2011 Arnica montana Ascorbic acid Hesperidin Rutoside Eriocitrin CITRUS BIOFLAVENOIDS Inhibits hyaluronaidase Decreases capillary permeability Collagen synthesis Capillary strength Capillary stability Inhibits elastase Decreases capillary permeability Antioxidant SARCOIDOSIS IF ANTI-MALARIALS, MTX AND STEROIDS FAIL SARCOIDOSIS AND MINOCYCLINE REFERENCE RESPONDED? COMMENT Dermatol Online J 2014 Aug 17;20(8) 1 of 1 Skin only JAMA Dermatol 2013;149: of 27 Skin only J Drugs Dermatol 2012;11: of 1 Hypopigmented Clin Rheumatol 2008;27: of 1 Ocular + Lung Arch Ophthalmol 2007;125: of 1 Ocular + Skin Arch Dermatol 2001;137: of 12 Skin only All at dose of 200mg/day Multiple mechanisms whereby minocycline might be anti-inflammatory in sarcoid (such as TNF-alfa and others), it also directly inhibits granuloma formation Arch Derm 1994;130:

6 SARCOIDOSIS AND INFLIXIMAB Inlfiximab is a chimeric monoclonal antibody which exerts its therapeutic effects by binding to TNF-alfa Infliximab not only binds to free cytokine, but also binds to tissue-bound TNF-alfa (That s why we worry about reactivation of TB, because TNF-alfa is necessary for granuloma formation and maintenance) Logical to administer to a non-infectious disease composed of granulomata STASIS ULCERS SIMVASTATIN AND STASIS ULCERS RCT of Rx chronic ( years) stasis ulcers n= 62 Divided equally: Simvastatin 40mg QD vrs placebo QD Both groups: adequate compression, elevation Ulcers < 5cm: Active Rx 100% versus placebo 50% healed Ulcers > 5cm: Active Rx 67% versus placebo 0% healed Large ulcers took about 9-10 weeks to heal MOA: unknown (?accelerated wound healing) Br J Dermatol 170:1151, 2014 CHONDRODERMATITIS NODULARIS HELICIS Standard therapy: Surgical removal; Topical/IL steroids Open label study (n=11) CNH Nitroglycerin patches 5mg/24hr, 12 hours daily, x 2 months 7/11 (63.6%) complete resolution 2 (18%) stopped Rx due to headache; 1(9%) non-responder MOA: Reversal of ischemia due to vasodilation? Supports prior work w/ nitroglycerin gel (2011) Dermatol Ther 27:278, 2014 HIDRADENITIS: METFORMIN Dermatol Ther 27:278, 2014 Refractory to Rx 25 patients (non-diabetic) Metformin 500mg BID to TID maximum, for 6 mo Majority (18/25) had improved Sartorious score, DLQI and PGA JEADV 27: , 2013 I often add finasteride (men) 5mg/d J Dermatol Treat 16:75-8,

7 HIDRADENITIS: OTHER Refractory to Rx n= 20 patients Open label, prospective 6mo Minocycline 100mg QD Colchicine 0.6mg BID Maintenance only colchicine at prior dosage (3mo) All cleared or improved! Aphthous Ulcers from Hell Int J Dermatol. 2017;56: VITAMIN B12 RCT with 58 patients Minimum 6 attacks/yr 1000mcg sublingual B12 QD vs placebo, 6 mo Active Rx: decreased number aphthae per month, decreased duration of each ulcer, decreased pain associated w/ ulcer By 6 mo, 74% ulcer-free Simple, Safe, Cheap J Am Board Fam Med 22:9, 2009 NICOTINE RAS rare in smokers, maybe because nicotine decreases cytokine and IL production and induces keratinization of oral mucosa Med Hypoth 77:185, 2011 Case report: 39 yo female w/ lifelong severe RAS Failed corticosteroids, colchicine, Abx Thalidomide worked, but developed neuropathy 4.5mg nicotine (lozenges) QD x 14 days, followed by 1.5mg lozenges TID x 6 mo (Australia) RAS-free In USA: 4mg and 2mg lozenges available OTC Australas J Dermatol 56:143, 2015 Hurricane Harvey Hurricane Irma Hurricane Maria HURRICANES AND FLOODS! HOUSTON 7

8 Int J Environ Res Public Health Jun 3;14(6). pii: E594. LEPTOSPIROSIS: CHEMOPROPHYLAXIS Comprehensive review and meta-analysis Doxycycline most widely used drug Single dose 200mg OR 200mg/week for 2-4 weeks PRE-exposure dosage significantly reduces morbidity and mortality POST-exposure dosage trends toward benefit but not statistically significant Int J Environ Res Public Health Jun 3;14(6). pii: E594. FLOOD COMING? TAKE 200MG DOXYCYCLINE! Lancet Infect Dis Dec 8. pii: S (17) Road to my office! POST-EXPOSURE BACTERIAL PROPHYLAXIS? French study; MSM who have condomless sexual contact All receiving PRE-exposure HIV prophylaxis Randomized: Single dose doxycycline 200mg within 24 hours versus no antibiotic within 24 hours of sexual contact (n=116 per group) Followup: 10 mos; Occurrence: chlamydia, GC, syphilis 22% presented with bacterial STD in prophylaxis group 42% presenting with bacterial STD in NO prophylaxis group (p =0.007) Adverse GI events: 53% PEP vs. 41% NO PEP (not stat signif) Lancet Infect Dis Dec 8. pii: S (17) RADICALLY DIFFERENT PEARLS THINK OUTSIDE THE BOX! USE RADICALLY DIFFERENT PEARLS Ted Rosen, MD Professor of Dermatology Baylor College of Medicine Houston, Texas 8

THINKING OUTSIDE THE BOX Ted Rosen, MD Baylor College of Medicine Houston, Texas

THINKING OUTSIDE THE BOX Ted Rosen, MD Baylor College of Medicine Houston, Texas THINKING OUTSIDE THE BOX Ted Rosen, MD Baylor College of Medicine Houston, Texas RADICAL TOPICAL THERAPEUTIC PEARLS {SOMETIMES BASED ON BASICS} Hong Kong Jade Market 2014 ZINC! DISCLOSURE OF RELATIONSHIPS

More information

New and Emerging Therapy Cutaneous Infectious Diseases

New and Emerging Therapy Cutaneous Infectious Diseases New and Emerging Therapy Cutaneous Infectious Diseases Ted Rosen, MD Professor of Dermatology Baylor College of Medicine Houston, Texas Disclosure S062 New and Emerging Therapies Conflict of Interest:

More information

Course 023 Derm Review No conflicts to declare

Course 023 Derm Review No conflicts to declare What s New in STD: 2018 Conflict of Interest Disclosure Course 023 Derm Review No conflicts to declare TED ROSEN, MD PROFESSOR OF DERMATOLOGY BAYLOR COLLEGE OF MEDICINE HOUSTON, TEXAS Why are STDs Important?

More information

Allergy, Atopy and Skin Cancer

Allergy, Atopy and Skin Cancer M. Shane Cahpman, MD, MBA: Dartmouth School of Medicine Boni E. Elewski, MD: University of Alabama Kenneth J. Tomecki, MD: Cleveland Clinic Ted Rosen, MD: Baylor College of Medicine Clinical and Therapeutic

More information

S016: Systemic Infections No conflicts for this talk

S016: Systemic Infections No conflicts for this talk Adventures in Syphilis Conflict of Interest Disclosure S016: Systemic Infections No conflicts for this talk TED ROSEN, MD PROFESSOR OF DERMATOLOGY BAYLOR COLLEGE OF MEDICINE HOUSTON, TEXAS Objectives Recognize

More information

Recalcitrant Warty Erythroderma With Severe Pruritus. Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University

Recalcitrant Warty Erythroderma With Severe Pruritus. Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University Recalcitrant Warty Erythroderma With Severe Pruritus Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY Gil Yosipovitch,

More information

No conflicts. The Hottest Topic: STDs Conflict of Interest Disclosure. Why are STDs Important?

No conflicts. The Hottest Topic: STDs Conflict of Interest Disclosure. Why are STDs Important? The Hottest Topic: STDs Conflict of Interest Disclosure No conflicts TED ROSEN, MD PROFESSOR OF DERMATOLOGY BAYLOR COLLEGE OF MEDICINE HOUSTON, TEXAS Why are STDs Important? Left untreated consequences

More information

Medical Therapy for Pediatric IBD: Efficacy and Safety

Medical Therapy for Pediatric IBD: Efficacy and Safety Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission

More information

Michael P. Heffernan, M.D San Luis Dermatology & Laser Clinic Director, US Probity Medical Research

Michael P. Heffernan, M.D San Luis Dermatology & Laser Clinic Director, US Probity Medical Research Michael P. Heffernan, M.D San Luis Dermatology & Laser Clinic Director, US Probity Medical Research mpheffernanmd@gmail.com DISCLOSURES Consultant, Speaker, Investigator: Abbvie, Amgen, Brickell Biotech,

More information

Orolabial Herpes: Fast Facts. Orolabial Herpes. Relevant Conflict of Interest Disclosure. Epidemiology Caucasian Females

Orolabial Herpes: Fast Facts. Orolabial Herpes. Relevant Conflict of Interest Disclosure. Epidemiology Caucasian Females Orolabial Herpes Simplex Old Disease: New Treatments Relevant Conflict of Interest Disclosure Advisory Board with honorarium: Cipher Ted Rosen, MD Professor of Dermatology Baylor College of Medicine Houston,

More information

Field vs Lesional Therapies for AKs 3/2/2019, 9:00-12 AM

Field vs Lesional Therapies for AKs 3/2/2019, 9:00-12 AM Dilemmas and Challenges in Skin Cancer Therapies and Management Field vs Lesional Therapies for AKs 3/2/2019, 9:00-12 AM Roger I. Ceilley, M.D. Clinical Professor of Dermatology The University of Iowa

More information

HEALTH SERVICES POLICY & PROCEDURE MANUAL

HEALTH SERVICES POLICY & PROCEDURE MANUAL PAGE 1 of 5 PURPOSE To assure that DOP inmates with skin lesions are receiving appropriate Primary Care for their lesions POLICY All DOP Primary Care Providers are expected to follow this guideline and/or

More information

Management of Chronic Idiopathic Urticaria

Management of Chronic Idiopathic Urticaria 9/3/216 Management of Chronic Idiopathic Urticaria Brian Berman, M.D., Ph.D. Professor Emeritus of Dermatology and Dermatologic Surgery, University of Miami Co-Director Center for Clinical and Cosmetic

More information

COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by North Lincolnshire CCG November 2012

COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by North Lincolnshire CCG November 2012 Drug, Treatment, Device name Omalizumab (Xolair; Novartis) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by North Lincolnshire CCG November 2012 Licensed indication Omalizumab

More information

Combination Nonbiologic Therapy in Psoriasis. Sushil Tahiliani, MBBS, MD

Combination Nonbiologic Therapy in Psoriasis. Sushil Tahiliani, MBBS, MD Combination Nonbiologic Therapy in Psoriasis Sushil Tahiliani, MBBS, MD Agenda Rationale Preferred and less preferred combination Morphology-specific preferred combinations Doses used in combinations Potential

More information

The Natural History of Psoriasis and Treatment Goals

The Natural History of Psoriasis and Treatment Goals The Natural History of Psoriasis and Treatment Goals Psoriasis Epidemiology Prevalence Affects 2 3% of adult population (>7 million in US) Caucasians: 25% 2.5% African Americans: 1.3% (more likely to have

More information

4/12/18. Refractory Chronic Urticaria: When Omalizumab Fails. Objectives. Disclosures

4/12/18. Refractory Chronic Urticaria: When Omalizumab Fails. Objectives. Disclosures Refractory Chronic Urticaria: When Omalizumab Fails David A. Khan, MD Professor of Medicine and Pediatrics Allergy & Immunology Program Director 1 Disclosures n Research Grants n NIH n Honoraria n UpToDate,

More information

The no t-so-simple cutaneous wart

The no t-so-simple cutaneous wart Salicylic acid is a commonly used over-the-counter treatment for nongenital warts. Clearance rates of up to 75% have been reported with salicylic acid. istockphoto 10 Clinical practice guide Dermatology

More information

INNATE IMMUNITY Non-Specific Immune Response. Physiology Unit 3

INNATE IMMUNITY Non-Specific Immune Response. Physiology Unit 3 INNATE IMMUNITY Non-Specific Immune Response Physiology Unit 3 Protection Against Infection The body has several defenses to protect itself from getting an infection Skin Mucus membranes Serous membranes

More information

VITAMIN D AND THE SKIN JOYCE FARAH MD MS FAAD FARAH DERMATOLOGY AND COSMETICS, LLC ASSISTANT PROFESSOR OF MEDICINE AND ENT UPSTATE MEDICAL UNIVERSITY

VITAMIN D AND THE SKIN JOYCE FARAH MD MS FAAD FARAH DERMATOLOGY AND COSMETICS, LLC ASSISTANT PROFESSOR OF MEDICINE AND ENT UPSTATE MEDICAL UNIVERSITY VITAMIN D AND THE SKIN JOYCE FARAH MD MS FAAD FARAH DERMATOLOGY AND COSMETICS, LLC ASSISTANT PROFESSOR OF MEDICINE AND ENT UPSTATE MEDICAL UNIVERSITY VIT D RECEPTORS ROLE IN MAINTAINING NORMAL FOLLICULAR

More information

Megha M. Tollefson, MD Associate Professor of Dermatology and Pediatrics, Mayo Clinic Pediatric Morphea March 1, MFMER

Megha M. Tollefson, MD Associate Professor of Dermatology and Pediatrics, Mayo Clinic Pediatric Morphea March 1, MFMER Megha M. Tollefson, MD Associate Professor of Dermatology and Pediatrics, Mayo Clinic Pediatric Morphea March 1, 2019 2015 MFMER 3513105-1 Disclosures None 2015 MFMER 3513105-2 Topics to cover Classification

More information

Chapter 11. Sexually Transmitted Diseases

Chapter 11. Sexually Transmitted Diseases Chapter 11. Sexually Transmitted Diseases General Guidelines Persons identified as having one sexually transmitted disease (STD) are at risk for others and should be screened as appropriate. Partners of

More information

Things that go bump: Wart & Molluscum

Things that go bump: Wart & Molluscum Things that go bump: Wart & Molluscum Raegan Hunt, MD, PhD Chief of Section, Pediatric Dermatology Texas Children s Hospital Disclosures Off label use of products may be discussed No relevant financial

More information

HPV Management in Special Populations

HPV Management in Special Populations HPV Management in Special Populations MELISSA KOTTKE, MD, MPH, MBA Disclosures Merck, Nexplanon trainer CSL Behring, Consultant Evofem, Advisory Board Most treatment options for HPV in special populations

More information

FRM F011 - Pearls: Diagnostic and Therapeutic

FRM F011 - Pearls: Diagnostic and Therapeutic FRM F011 - Pearls: Diagnostic and Therapeutic I have uploaded these slides as a handout, and will replace them with the ones actually used in the presentation when I get home or you can email me at sstone@siumed.edu

More information

Review Acne Pathogenesis Clinical Evaluation Treatment Guidelines

Review Acne Pathogenesis Clinical Evaluation Treatment Guidelines Tiffany Herd, MD Pediatric Dermatology Fellow Baylor College of Medicine/Texas Children's Hospital Review Acne Pathogenesis Clinical Evaluation Treatment Guidelines Psychosocial Impact of Acne Acne is

More information

Ulcerative Colitis Therapy. Faculty Disclosure. Acknowledgements 28/11/2013. Amy Morse November 30/13

Ulcerative Colitis Therapy. Faculty Disclosure. Acknowledgements 28/11/2013. Amy Morse November 30/13 Ulcerative Colitis Therapy Amy Morse November 30/13 GI for GP s Jasper AB Faculty Disclosure Faculty: Amy Morse Relationships with commercial interests: Grants/Research Support: Therapeutic Fellowship

More information

Index. derm.theclinics.com. Note: Page numbers of article titles are in boldface type.

Index. derm.theclinics.com. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Abatacept for DLE, 493 for SLE, 497 Ablative therapies, localized, for cutaneous T-cell lymphoma, 502 506. See also Cutaneous T-cell lymphoma,

More information

Deep Dermatophytosis

Deep Dermatophytosis Deep Dermatophytosis 2016-11-06 MMTN/Bangkok Department of Dermatology Chang Gung Memorial Hospital, Linkou Branch Taoyuan, Taiwan Superficial dermatophytosis Wikimedia Stratum corneum Tinea faciei Tinea

More information

Update on systemic therapies and emerging treatments How do I choose a systemic agent?

Update on systemic therapies and emerging treatments How do I choose a systemic agent? Update on systemic therapies and emerging treatments How do I choose a systemic agent? Amy S. Paller, M.D. Walter J. Hamlin Professor and Chair of Dermatology Professor of Pediatrics Northwestern University

More information

How to Successfully Manage Chronic Urticaria? & Tall Tales from Texas

How to Successfully Manage Chronic Urticaria? & Tall Tales from Texas How to Successfully Manage Chronic Urticaria? & Tall Tales from Texas David A. Khan, MD Professor of Medicine and Pediatrics Allergy & Immunology Program Director 1 Disclosures Honoraria/Speakers Bureau

More information

Anti-TNF biologic agents Dr Lluís Puig

Anti-TNF biologic agents Dr Lluís Puig Department of Dermatology Hospital de la Santa Creu i Sant Pau IPC NOVARTIS PSORIASIS PRECEPTORSHIP Anti-TNF biologic agents Dr Lluís Puig Barcelona, July 9th-10th, 2013 Anti-TNF therapy in the pathophysiology

More information

COMPLEX CUTANEOUS LUPUS CASES PEARLS AND PITFALLS

COMPLEX CUTANEOUS LUPUS CASES PEARLS AND PITFALLS COMPLEX CUTANEOUS LUPUS CASES PEARLS AND PITFALLS Benjamin F. Chong, MD, MSCS February 17, 2018 CONFLICTS OF INTEREST D I S CLOSURE OF R E LATI ONSHIPS W I T H I NDUSTRY Benjamin Chong, MD, MSCS F059 Complex

More information

Comparison of immunogenicity of 2-dose and 3-dose regimens of 9-valent HPV vaccine Advisory Committee on Immunization Practices 24-Feb-2016

Comparison of immunogenicity of 2-dose and 3-dose regimens of 9-valent HPV vaccine Advisory Committee on Immunization Practices 24-Feb-2016 1 Comparison of immunogenicity of 2-dose and 3-dose regimens of 9-valent HPV vaccine Advisory Committee on Immunization Practices 24-Feb-2016 Presenter: Alain Luxembourg, MD, PhD Director, Clinical Research

More information

Update on Sexually Transmitted Infections Jeanne Marrazzo, MD, MPH

Update on Sexually Transmitted Infections Jeanne Marrazzo, MD, MPH Update on Sexually Transmitted Infections Jeanne Marrazzo, MD, MPH Division of Infectious Diseases University of Alabama at Birmingham School of Medicine Birmingham, Alabama Outline Syphilis in all its

More information

Answers to those burning questions -

Answers to those burning questions - Answers to those burning questions - Ann Avery MD Infectious Diseases Physician-MetroHealth Medical Center Assistant Professor- Case Western Reserve University SOM Medical Director -Cleveland Department

More information

Why the basics? Back to Basics HIV Dermatology Immune reconstitution Acne. The HIV infected pt who starts ARV s 12/12/2012

Why the basics? Back to Basics HIV Dermatology Immune reconstitution Acne. The HIV infected pt who starts ARV s 12/12/2012 Why the basics? Back to Basics HIV Dermatology 2012 Toby Maurer, MD University of California, San Francisco 1) The depleted low CD4 counts 2) The repleted aging pts 3) The group who starts ARV s at high

More information

OPPORTUNISTIC INFECTIONS. Institute of Infectious Diseases, Pune India

OPPORTUNISTIC INFECTIONS. Institute of Infectious Diseases, Pune India OPPORTUNISTIC INFECTIONS Institute of Infectious Diseases, Pune India DISCLOSURES Nothing to declare Outline The problem Bacterial Fungal Protozoal Viral Decline in OI prevalence in HAART era: USA CROI

More information

Medical Dermatology Highlights Eric Hossler, MD Program Director, Dermatology Associate, Dermatopathology Geisinger Medical Center

Medical Dermatology Highlights Eric Hossler, MD Program Director, Dermatology Associate, Dermatopathology Geisinger Medical Center Medical Dermatology Highlights 2017 Eric Hossler, MD Program Director, Dermatology Associate, Dermatopathology Geisinger Medical Center I have no relevant financial relationships with commercial interest(s).

More information

Tinea: Head to Toe A dermatophyte tour of human skin. Tour de Tinea Head to Toe. Tips for Tinea Head to Toe. Psoriasis. Non-inflammatory Tinea Capitis

Tinea: Head to Toe A dermatophyte tour of human skin. Tour de Tinea Head to Toe. Tips for Tinea Head to Toe. Psoriasis. Non-inflammatory Tinea Capitis Tinea: Head to Toe A dermatophyte tour of human skin Renee Howard, MD Assistant Clinical Professor of Dermatology, UCSF Tour de Tinea Head to Toe Tips for Tinea Head to Toe Capitis Faciei Corporis Pedis

More information

Sarcoidosis Case. Robert P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic University of Cincinnati, USA. WASOG: educational material

Sarcoidosis Case. Robert P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic University of Cincinnati, USA. WASOG: educational material Sarcoidosis Case Robert P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic University of Cincinnati, USA WASOG: educational material Sarcoidosis Case patient is a Caucasian male age 46 was diagnosed

More information

Immunology. Lecture- 8

Immunology. Lecture- 8 Immunology Lecture- 8 Immunological Disorders Immunodeficiency Autoimmune Disease Hypersensitivities Immunodeficiency 1. Immunodeficiency --> abnormal production or function of immune cells, phagocytes,

More information

The Great Imitator Revealed: Syphilis

The Great Imitator Revealed: Syphilis The Great Imitator Revealed: Syphilis Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health University of California Los Angeles David Geffen School of Medicine Los Angeles, California Learning

More information

Right type of lesions for topicals. Onychomycosis. Common Diseases and Infections of the SKIN. Toby Maurer, MD University of California, San Francisco

Right type of lesions for topicals. Onychomycosis. Common Diseases and Infections of the SKIN. Toby Maurer, MD University of California, San Francisco Common Diseases and Infections of the SKIN Toby Maurer, MD University of California, San Francisco Onychomycosis Topical treatment use for the right type of lesions Naftin gel for small superficial lesions

More information

Emerging Use of Topical Biologics in Limb Salvage Role of Activated Collagen in Multimodality Treatment

Emerging Use of Topical Biologics in Limb Salvage Role of Activated Collagen in Multimodality Treatment 9 th Annual New Cardiovascular Horizons New Orleans September 12, 2008 Emerging Use of Topical Biologics in Limb Salvage Role of Activated Collagen in Multimodality Treatment Gary M. Rothenberg, DPM, CDE,

More information

Contents. QAaptm-2. CAaptei-3. CAaptm-4. Cftapte%-5. Qfiaptvt-6. QhapteK-7. Qkaptefc-8 Clinical Immunology and Allergy 71

Contents. QAaptm-2. CAaptei-3. CAaptm-4. Cftapte%-5. Qfiaptvt-6. QhapteK-7. Qkaptefc-8 Clinical Immunology and Allergy 71 Contents Ckaptm-1 Aaatomy, Physiology, Embryology, Bacteriology and Pathology ~ 1 Anatomy 1 Physiology 10 Embryology 14 Pathology 19 Bacteriology 22 Laboratory and other aids in dermatological pratice

More information

Mechanisms of disease

Mechanisms of disease PP Mechanisms of disease Stress and disease Homeostasis - Responsible for maintaining a constant, safe internal environment - Controlled by feedback loops o Negative feedback loop: temperature, blood glucose

More information

Osteopathic Dermatology

Osteopathic Dermatology Osteopathic Dermatology Teodor Huzij, DO, FACN Reagan Anderson, DO, FAOCD, FASMS, Certificate of Added Qualification for Mohs Surgery, MPH, MCS, Program Director for RVU/CDI Dermatology Residency Program

More information

Anaphylactic response in rabbit Part II

Anaphylactic response in rabbit Part II Anaphylactic response in rabbit Part II Introduction Four types of hypersensitivity reactions: Type I: allergy Type II: antibodies Type III: immune complex Type IV: T-cells Type I Hypersensitivity ALLERGY

More information

Resurgence of (many) STDs

Resurgence of (many) STDs Resurgence of (many) STDs TED ROSEN, MD PROFESSOR OF DERMATOLOGY BAYLOR COLLEGE OF MEDICINE HOUSTON, TEXAS 1 Conflict of Interest NONE 2 1 Resurgent STDs Carnival Las Tablas, Republic of Panama 3 4 2 Sex

More information

New Drugs for Uveitis. Medical Eye Unit St Thomas Hospital

New Drugs for Uveitis. Medical Eye Unit St Thomas Hospital New Drugs for Uveitis Miles Stanford Medical Eye Unit St Thomas Hospital x Epithelium x x Antigen Y Y Y Y IgG m cd4 IL-2 Y m + IL-12 Cytotoxic T B pmn Ig s PG s. LTB4 O - IL-6 TNFα IFNγγ IL-2 Th1 IL-10

More information

Psoriasiform Dermatitis in Children: Calling in the Troops

Psoriasiform Dermatitis in Children: Calling in the Troops Psoriasiform Dermatitis in Children: Calling in the Troops Markus Boos, MD PhD Attending Physician, Dermatology Seattle Children s Hospital Assistant Professor of Pediatrics, University of Washington School

More information

Andrei Metelitsa, MD, FRCPC, FAAD Co-Director, Institute for Skin Advancement Clinical Associate Professor, Dermatology University of Calgary, Canada

Andrei Metelitsa, MD, FRCPC, FAAD Co-Director, Institute for Skin Advancement Clinical Associate Professor, Dermatology University of Calgary, Canada Andrei Metelitsa, MD, FRCPC, FAAD Co-Director, Institute for Skin Advancement Clinical Associate Professor, Dermatology University of Calgary, Canada Copyright 2017 by Sea Courses Inc. All rights reserved.

More information

BL-5010P A NOVEL PRE-FILLED APPLICATOR FOR THE NON-SURGICAL REMOVAL OF SKIN LESIONS

BL-5010P A NOVEL PRE-FILLED APPLICATOR FOR THE NON-SURGICAL REMOVAL OF SKIN LESIONS BL-5010P A NOVEL PRE-FILLED APPLICATOR FOR THE NON-SURGICAL REMOVAL OF SKIN LESIONS 25 Skin lesions Miri Seiberg, PhD 26 Skin lesions A part of the skin that has an abnormal growth or appearance compared

More information

Interesting Case Series. Skin Grafting in Pyoderma Gangrenosum

Interesting Case Series. Skin Grafting in Pyoderma Gangrenosum Interesting Case Series Skin Grafting in Pyoderma Gangrenosum Marco Romanelli, MD, PhD, Agata Janowska, MD, Teresa Oranges, MD, and Valentina Dini, MD, PhD Department of Dermatology, University of Pisa,

More information

Everant.in/index.php/jmpr. Journal of Medical Practice and Review

Everant.in/index.php/jmpr. Journal of Medical Practice and Review Everant.in/index.php/jmpr Journal of Medical Practice and Review Real world Efficacy and Tolerance of Bepotastine, a new 2 nd generation antihistamine, in Pruritis and other symptoms associated with cutaneous

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.

More information

Dermatopathology Case Challenge: Recognizing Mimics and Masqueraders

Dermatopathology Case Challenge: Recognizing Mimics and Masqueraders Dermatopathology Case Challenge: Recognizing Mimics and Masqueraders Rosalie Elenitsas, M.D. Professor of Dermatology Director, Dermatopathology University of Pennsylvania DISCLOSURE OF RELATIONSHIPS WITH

More information

Bugs and Drugs: What s New in Hypersensitivity Reactions?

Bugs and Drugs: What s New in Hypersensitivity Reactions? Bugs and Drugs: What s New in Hypersensitivity Reactions? Erin Mathes, MD Associate Professor of Dermatology and Pediatrics University of California, San Francisco DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY

More information

TUBERCULOSIS AND THE TNF-α INHIBITORS. Lloyd Friedman, M.D. Yale University Milford Hospital

TUBERCULOSIS AND THE TNF-α INHIBITORS. Lloyd Friedman, M.D. Yale University Milford Hospital TUBERCULOSIS AND THE TNF-α INHIBITORS Lloyd Friedman, M.D. Yale University Milford Hospital Outline TNF-α Anti-TNF-α medications Rates of tuberculosis Lower rates with etanercept Screening for latent tuberculosis

More information

Efficacy and Safety of Treatment for Pediatric IBD

Efficacy and Safety of Treatment for Pediatric IBD Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,

More information

Non-Steroidal Anti- Inflammatory Drugs. ATPE 410 Chapter 6

Non-Steroidal Anti- Inflammatory Drugs. ATPE 410 Chapter 6 Non-Steroidal Anti- Inflammatory Drugs ATPE 410 Chapter 6 Inflammatory Process A normal, beneficial process that begins immediately after injury to facilitate repair and return the tissue to normal function

More information

Evolving therapies for posterior uveitis. Infliximab (Remicade) Infliximab: pharmacology. FDA-approved monoclonal antibody therapy Target

Evolving therapies for posterior uveitis. Infliximab (Remicade) Infliximab: pharmacology. FDA-approved monoclonal antibody therapy Target Evolving therapies for posterior uveitis Sam Dahr, M.D. September 17, 2005 Midwest Ophthalmology Conference Infliximab (Remicade) FDA approved for Crohn s disease, rheumatoid arthritis, and psoriatic arthritis

More information

Sexually transmitted infections (in women)

Sexually transmitted infections (in women) Sexually transmitted infections (in women) Timothy Kremer, MD Assistant Professor, Department of Obstetrics and Gynecology University of North Texas Health Science Center Last official CDC guidelines:

More information

Psoriasis management. A/Prof Amanda Oakley Dermatologist, Waikato

Psoriasis management. A/Prof Amanda Oakley Dermatologist, Waikato Psoriasis management A/Prof Amanda Oakley Dermatologist, Waikato AbbVie Breakfast Session, 14 June 2014 Disclosure This breakfast session is sponsored by Abbvie Autoimmune skin disorders Psoriasis Eczema

More information

Treatment Options for Refractory Urticaria

Treatment Options for Refractory Urticaria Treatment Options for Refractory Urticaria David A. Khan, MD Professor of Medicine Allergy & Immunology Program Director Division of Allergy & Immunology University of Texas Southwestern Medical Center

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Omalizumab Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 6 References... 7 Effective Date... 3/15/2018 Next

More information

Atopic Dermatitis: Therapeutic Challenges

Atopic Dermatitis: Therapeutic Challenges Atopic Dermatitis: Therapeutic Challenges PDA August 14, 2009 Jon Hanifin OHSU, Portland Dominant Concepts in Atopic Dermatitis Allergy / Immunology Era: 1915-2006 The Epidermal Era: 2006---- Barrier dysfunction

More information

DISCLOSURES WHAT S NEW AND EXCITING FROM JAAD

DISCLOSURES WHAT S NEW AND EXCITING FROM JAAD WHAT S NEW AND EXCITING FROM JAAD Bruce H. Thiers, MD, Editor, JAAD Professor, Medical University of South Carolina Department of Dermatology and Dermatologic Surgery DISCLOSURES PFIZER VALEANT EFFECT

More information

Wound Healing Stages

Wound Healing Stages Normal Skin Wound Healing Stages Stages overlap Chronic wounds are stalled in the inflammatory phase COLLAGEN MATURATION MATRIX METALLOPROTEINASES ENDOTHELIAL CELLS EPITHELIAL CELLS MATRIX PROTEINS FIBROBLASTS

More information

Systemic Medications for the Dermatology Toolbox: Potassium Iodide Handout for Key Points

Systemic Medications for the Dermatology Toolbox: Potassium Iodide Handout for Key Points Systemic Medications for the Dermatology Toolbox: Potassium Iodide Handout for Key Points Taraneh Paravar, MD Assistant Professor Department of Dermatology, UC San Diego March 3, 2017 DISCLOSURE OF RELATIONSHIPS

More information

12/12/2018. Childhood Skin Infections. Objectives. Verruca vulgaris. Case #1. Case #2. Management 1. Evidence Updates

12/12/2018. Childhood Skin Infections. Objectives. Verruca vulgaris. Case #1. Case #2. Management 1. Evidence Updates Objectives Childhood Skin Infections Evidence Updates Brian Z. Rayala, MD Associate Professor Department of Family Medicine UNC School of Medicine At the end of lecture, learner will be able to:» Diagnose

More information

Fungal Resistance, Biofilm, and Its Impact In the Management of Nail Infection

Fungal Resistance, Biofilm, and Its Impact In the Management of Nail Infection Fungal Resistance, Biofilm, and Its Impact In the Management of Nail Infection Faculty Raza Aly, PhD, MPH Professor Emeritus University of California Medical Center (MSSF) Professor, Dermatology Faculty

More information

Cutaneous warts are one of the most common

Cutaneous warts are one of the most common A Highly Effective Topical Compounded Medication for the Treatment of Cutaneous Warts A compounded formulation with an adhesive vehicle shows promise for one of the most common and frustrating conditions

More information

Immunotherapy of Warts

Immunotherapy of Warts Immunotherapy of Warts Jacob Mashiah, MD, MHA Dermatology and Pediatric Dermatology Dana-Dowek children s hospital Sourasky Medical Center Tel-Aviv, Israel No conflict of interest to disclose Human Papillomavirus

More information

REPRINT REPRIN REPRINT REP. Cutaneous warts are one of the most common

REPRINT REPRIN REPRINT REP. Cutaneous warts are one of the most common A Highly Effective Topical Compounded Medication for the Treatment of Cutaneous Warts A compounded formulation with an adhesive vehicle shows promise for one of the most common and frustrating conditions

More information

Meds and Falls: Keep in Step with your Meds

Meds and Falls: Keep in Step with your Meds Meds and Falls: Keep in Step with your Meds Donna Bartlett PharmD, CGP, RPh Associate Professor-Pharmacy Practice MCPHS University Clinical Pharmacist-MCPHS University- Pharmacy Outreach Program donna.bartlett@mcphs.edu

More information

Treatment with steroids and immunosuppressants

Treatment with steroids and immunosuppressants Treatment with steroids and immunosuppressants Donna Culton, MD, PhD University of North Carolina IPPF 2017 Annual Patient Conference Newport Beach, CA September 16, 2017 Factors that will influence therapy

More information

Itraconazole DIGICON. Composition: MOLECULAR INTRODUCTION

Itraconazole DIGICON. Composition: MOLECULAR INTRODUCTION Itraconazole DIGICON Composition: Itraconazole 100 mg MOLECULAR INTRODUCTION Itraconazole is a triazole medicine used to treat fungal infections. It is effective against a broad spectrum of fungi including:

More information

The Skinny of the Immune System

The Skinny of the Immune System The Skinny of the Immune System Robert Hostoffer, DO, FACOP, FAAP Associate Professor of Pediatrics Case Western Reserve University, Cleveland, Ohio Overview 1. Immune system of the skin 2. Immune Players

More information

Drugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending

Drugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending Policy Subject: Anti-TNF Agents Policy Number: SHS PBD16 Category: Rheumatology & Autoimmune Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual

More information

BIOH122 Session 8 Non-Specific Disease Resistance

BIOH122 Session 8 Non-Specific Disease Resistance BIOH122 Session 8 Non-Specific Disease Resistance To complete this worksheet, select: Module: Disease Resistance Activity: Animations Title: Non-Specific Disease Resistance Introduction 1. Name five general

More information

Innate vs Adaptive Response

Innate vs Adaptive Response General Immunology Innate vs Adaptive Response Innate- non-specific (4 types of barriers) anatomic- ato mechanical ca (skin), ph, mucous, normal flora Physiologic- temperature, ph, chemicals (lysozyme,

More information

INFLAMMATION & REPAIR

INFLAMMATION & REPAIR INFLAMMATION & REPAIR Lecture 7 Chemical Mediators of Inflammation Winter 2013 Chelsea Martin Special thanks to Drs. Hanna and Forzan Course Outline i. Inflammation: Introduction and generalities (lecture

More information

Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)

Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review

More information

Stevens-Johnson s Syndrome / Toxic Epidermal Necrolysis: An update

Stevens-Johnson s Syndrome / Toxic Epidermal Necrolysis: An update Stevens-Johnson s Syndrome / Toxic Epidermal Necrolysis: An update Robert G. Micheletti, MD Assistant Professor of Dermatology and Medicine Director, Cutaneous Vasculitis Clinic, Penn Vasculitis Center

More information

Table of Contents. Injectable Gel with 0.3% Lidocaine

Table of Contents. Injectable Gel with 0.3% Lidocaine Patient Brochure Table of Contents About Restylane-L 4 Safety 6 Post-Marketing Surveillance 9 About the Procedure 10 Troubleshooting 11 Injectable Gel with 0.3% Lidocaine 2 3 About Restylane-L Q What is

More information

EGFR inhibitors. EGFR inhibitors. Cutaneous side effects of EGFRinhibitors. EGFR inhibitor skin toxicity. EGFR is abundantly expressed in the skin

EGFR inhibitors. EGFR inhibitors. Cutaneous side effects of EGFRinhibitors. EGFR inhibitor skin toxicity. EGFR is abundantly expressed in the skin TARGETED THERAPIES AND THEIR CUTANEOUS TOXICITIES Brussels, 14/1/2017 Cutaneous side effects of EGFRinhibitors and their management Siegfried Segaert Dermatology Dept University Hospital Leuven Belgium

More information

Evaluating Psoriasis: Patient Reported Outcomes and Impact of Disease

Evaluating Psoriasis: Patient Reported Outcomes and Impact of Disease Evaluating Psoriasis: Patient Reported Outcomes and Impact of Disease Bruce E. Strober, MD, PhD Professor and Chair Department of Dermatology University of Connecticut Farmington, Connecticut DISCLOSURE

More information

Asymptomatic Undiagnosed Lichen Sclerosus

Asymptomatic Undiagnosed Lichen Sclerosus Asymptomatic Undiagnosed Lichen Sclerosus Lynette J. Margesson MD FRCPC Assistant Professor of Obstetrics & Gynecology and Surgery(Dermatology) Geisel School of Medicine at Dartmouth Lebanon, NH, USA Disclosures

More information

2/18/19. Case 1. Question

2/18/19. Case 1. Question Case 1 Which of the following can present with granulomatous inflammation? A. Sarcoidosis B. Necrobiotic xanthogranulma C. Atypical mycobacterial infection D. Foreign Body Reaction E. All of the above

More information

Uveitis unplugged: systemic therapy

Uveitis unplugged: systemic therapy Uveitis unplugged: systemic therapy Hobart 2017 Peter McCluskey Save Sight Institute Sydney Eye Hospital Sydney Medical School University of Sydney Sydney Australia No financial or proprietary interest

More information

IL-17 in health and disease. March 2014 PSO13-C051n

IL-17 in health and disease. March 2014 PSO13-C051n IL-17 in health and disease March 2014 PSO13-C051n Originally Researchers Suggested That IL-12 and IL-4 drove Th Cell Differentiation Naïve CD4 + T cell Question: Which of these cell types is responsible

More information

Cutaneous Immunology: Innate Immune Responses. Skin Biology Lecture Series

Cutaneous Immunology: Innate Immune Responses. Skin Biology Lecture Series Cutaneous Immunology: Innate Immune Responses Skin Biology Lecture Series The Immune Response: Innate and Adaptive Components Source: Wolff, Goldsmith, Katz, Gilchrest, Paller, Leffell. Fitzpatrick s Dermatology

More information

An Update on Topical Therapy for Atopic Dermatitis

An Update on Topical Therapy for Atopic Dermatitis An Update on Topical Therapy for Atopic Dermatitis Amy S. Paller, M.D. Professor and Chair of Dermatology Professor of Pediatrics Northwestern University Feinberg School of Medicine Chicago, Illinois Disclosures

More information

Sexually Transmitted Infection Treatment and HIV Prevention

Sexually Transmitted Infection Treatment and HIV Prevention Sexually Transmitted Infection Treatment and HIV Prevention Toye Brewer, MD Co-Director, Fogarty International Training Program University of Miami Miller School of Medicine STI Treatment and HIV Prevention.

More information

5/1/2017. Sexually Transmitted Diseases Burning Questions

5/1/2017. Sexually Transmitted Diseases Burning Questions Sexually Transmitted Diseases Burning Questions Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health University of California Los Angeles Los Angeles, California FORMATTED: 04-03-17 Financial

More information

Case 1 History. William Tremaine, M.D. CP

Case 1 History. William Tremaine, M.D. CP Extraintestinal Manifestations of IBD Case Studies William Tremaine, M.D. Case 1 History 18 year-old woman with Crohn s disease Onset at age 5: colonic & perianal Sulfasalazine, prednisone, mercaptopurine

More information

MUCOCUTANEOUS MANIFESTATIONS OF HIV/AIDS IN ADOLESCENTS

MUCOCUTANEOUS MANIFESTATIONS OF HIV/AIDS IN ADOLESCENTS MUCOCUTANEOUS MANIFESTATIONS OF HIV/AIDS IN ADOLESCENTS Dr. Y.S.MARFATIA Prof. and Head, Dept. Skin & V.D. Medical college, Vadodara LET US CREATE BRILLIANCE TOGETHER MEDICAL COLLEGE, VADODARA Editor in

More information

Biologics in Psoriasis. Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre

Biologics in Psoriasis. Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre Biologics in Psoriasis Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre Disclosures Consultancy services for Celgene, Centocor, Almirall, Amgen, Pfizer, Philips,

More information